We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Vertex ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Vertex Pharmaceuticals hit a rough patch in Q1, reporting weaker-than-expected earnings and halting an early mRNA cystic ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Vertex Pharmaceuticals (VRTX) and Neurocrine Biosciences (NBIX) shares are moving sharply after their respective earnings ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were ...